NRSN

NeuroSense Therapeutics (NRSN)

About NeuroSense Therapeutics (NRSN)

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm offers PrimeC, a therapy for amyotrophic lateral sclerosis (ALS). It also conducts testing of product candidates for the treatment of Parkinson's and Alzheimer's diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

Details

Daily high

$0.96

Daily low

$0.86

Price at open

$0.87

52 Week High

$2.60

52 Week Low

$0.68

Market cap

25.8M

Dividend yield

0.00%

Volume

611

Avg. volume

262,743

P/E ratio

-1.49

NeuroSense Therapeutics News